Filing Flows › iSpecimen (ISPC) › Q3 2025
iSpecimen (ISPC) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 17, 2025
iSpecimen (ISPC) reported revenue of $107K for the third quarter 2025 (Q3 2025), -96% from a year earlier and -85% from the quarter before.
iSpecimen, Q3 2025: revenue $107K (-96% year over year), net loss $2.8M, operating cash flow −$2.0M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $107K | -85% | -96% |
| Operating profit | −$2.8M | — | — |
| Net earnings | −$2.8M | — | — |
| Operating cash flow | −$2.0M | — | — |
What changed
Revenue was $107K in Q3 2025, down 96% year over year and down 85% from the previous quarter. Product was the largest line at 90% of revenue. Product lost $2.5M year over year (down 96%), 99% of the total change.
Operating costs exceeded revenue by $2.8M, an operating margin of -2655.2%. Total costs fell 33% while revenue fell 96%. The fastest-growing cost line was Sales & marketing (+81%). The quarter ended with a net loss of $2.8M, wider than the previous quarter's $1.0M loss.
Operating cash flow was −$2.0M. Non-cash charges added back $458K of depreciation and amortization and $2K of share-based compensation. Working capital and other items added $286K.
Questions
What was iSpecimen's revenue in the third quarter 2025?
iSpecimen (ISPC) reported revenue of $107K for the third quarter 2025 (Q3 2025), -96% from a year earlier and -85% from the quarter before.
Source: iSpecimen 10-Q on SEC EDGAR.